Evidence map›Paper›PMID 40585839›Full record

ReviewWorld journal of clinical oncology2025

Advances and challenges in pathomics for liver cancer: From diagnosis to prognostic stratification.

Ming-Hui Peng, Kai-Lun Zhang, Shi-Wei Guan, Quan Lin, Hai-Bo Yu

Abstract readReview
In one paragraph

Review in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ming-Hui PengDepartment of Hepatobiliary Surgery, The Dingli Clinical Institute of Wenzhou Medical University (Wenzhou Central Hospital), Wenzhou 325000, Zhejiang Province, China.
Kai-Lun ZhangDepartment of Hepatobiliary Surgery, The Dingli Clinical Institute of Wenzhou Medical University (Wenzhou Central Hospital), Wenzhou 325000, Zhejiang Province, China.
Shi-Wei GuanDepartment of Hepatobiliary Surgery, The Dingli Clinical Institute of Wenzhou Medical University (Wenzhou Central Hospital), Wenzhou 325000, Zhejiang Province, China.
Quan LinDepartment of Hepatobiliary Surgery, The Dingli Clinical Institute of Wenzhou Medical University (Wenzhou Central Hospital), Wenzhou 325000, Zhejiang Province, China.
Hai-Bo YuDepartment of Hepatobiliary Surgery, The Dingli Clinical Institute of Wenzhou Medical University (Wenzhou Central Hospital), Wenzhou 325000, Zhejiang Province, China. zjuboby@zuaa.zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC), a leading cause of cancer mortality, faces diagnostic and therapeutic challenges due to its histopathological complexity and clinical heterogeneity. Pathomics, an emerging discipline that integrates artificial intelligence (AI) with quantitative pathology image analysis, aims to decode disease heterogeneity by extracting high-dimensional features from histopathological specimens. This review highlights how AI-driven pathomics has revolutionized liver cancer management through automated analysis of whole-slide images. Pathomics integrates deep learning with histopathological features to enable precise tumour classification (

Indexed as

Artificial intelligenceDeep learningDigital pathologyLiver cancerMicrovascular invasionMultiomics integrationPathomicsPrognostic biomarkersTumor recurrenceWhole-slide imaging

Identifiers

PMID40585839
PMCPMC12198871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.